Our studies using the isogenic COX-1 cell lines are in line with previous studies showing that COX-1 inhibitors are more effective than COX-2 inhibitors in suppressing tumor growth in preclinical ovarian cancer models [10–12, 14–17]. This evidence concerns the gene PTGER2 and neoplasm.